336 related articles for article (PubMed ID: 17571086)
1. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.
Konstas AG; Katsimpris IE; Kaltsos K; Georgiadou I; Kordelou A; Nelson LA; Stewart WC
Eye (Lond); 2008 Nov; 22(11):1391-7. PubMed ID: 17571086
[TBL] [Abstract][Full Text] [Related]
2. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
3. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
5. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
García-Feijoó J; Sáenz-Francés F; Martínez-de-la-Casa JM; Méndez-Hernández C; Fernández-Vidal A; Calvo-González C; García-Sánchez J
Curr Med Res Opin; 2010 Jul; 26(7):1599-606. PubMed ID: 20429818
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
[TBL] [Abstract][Full Text] [Related]
8. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma.
Konstas AG; Holló G; Mikropoulos D; Tsironi S; Haidich AB; Embeslidis T; Georgiadou I; Irkec M; Melamed S
Br J Ophthalmol; 2010 Feb; 94(2):209-13. PubMed ID: 19825835
[TBL] [Abstract][Full Text] [Related]
9. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
Diestelhorst M; Larsson LI;
Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
[TBL] [Abstract][Full Text] [Related]
10. Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma.
Yüksel N; Gök M; Altıntaş O; Cağlar Y
Curr Eye Res; 2011 Sep; 36(9):804-8. PubMed ID: 21851166
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma.
Konstas AG; Mikropoulos D; Haidich AB; Ntampos KS; Stewart WC
Br J Ophthalmol; 2009 Apr; 93(4):481-5. PubMed ID: 19019932
[TBL] [Abstract][Full Text] [Related]
13. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
14. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma.
Konstas AG; Tsironi S; Vakalis AN; Nasr MB; Stewart JA; Nelson LA; Stewart WC
Acta Ophthalmol; 2009 Feb; 87(1):71-6. PubMed ID: 19178390
[TBL] [Abstract][Full Text] [Related]
15. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy.
Konstas AG; Mikropoulos D; Dimopoulos AT; Moumtzis G; Nelson LA; Stewart WC
Br J Ophthalmol; 2008 Nov; 92(11):1498-502. PubMed ID: 18703549
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.
Goldberg I; Crowston JG; Jasek MC; Stewart JA; Stewart WC;
J Glaucoma; 2012 Jan; 21(1):55-9. PubMed ID: 21048504
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
